home.social

#chronic-fatigue — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #chronic-fatigue, aggregated by home.social.

fetched live
  1. For the Spoonie Community, I fall asleep because I have no spoons and I wake up an hour later having recovered...no spoons

    You know what I mean

    #Spoonie #MultipleSclerosis #ChronicFatigue

  2. ✨ Whether you are navigating the pressure of a high stakes career, carrying ancestral patterns, struggling in difficult relationships, or healing from a broken heart, the real solution lies in recalibrating your energetic field. ... You are always welcome here.
    Link in profile.
    💗
    #mentalhealth
    #ChronicFatigue #BrainFog #SleepBetter #MigraineRelief #ChronicPain #DigitalDetox #MentalLoad #work #career #meditation

    Made with ai tools.

  3. CPAP fact: You can have need of a CPAP without snoring! I had a good doc who was trying to diagnose my then-mysterious fatigue. When the usual tests showed nothing, they wanted me to do a sleep test.

    I protested. I didn't perceive myself to have a sleep problem, and my husband never heard me snore. Finally I gave in and went, and sure enough I had sleep apnea. It was just quiet.

    This wasn't the whole answer to my fatigue but it helped a great deal, and had that doc not pushed, I don't think I'd ever know this. Sleep tests are very easy now! No more nights at labs, covered in wires. You can take one at home with light monitoring. If you even suspect you could benefit, try it. They help a lot if you need them.

    #ChronicFatigue #Fibromyalgia #MECFS #ChronicIllness #CPAP

  4. CPAP fact: You can have need of a CPAP without snoring! I had a good doc who was trying to diagnose my then-mysterious fatigue. When the usual tests showed nothing, they wanted me to do a sleep test.

    I protested. I didn't perceive myself to have a sleep problem, and my husband never heard me snore. Finally I gave in and went, and sure enough I had sleep apnea. It was just quiet.

    This wasn't the whole answer to my fatigue but it helped a great deal, and had that doc not pushed, I don't think I'd ever know this. Sleep tests are very easy now! No more nights at labs, covered in wires. You can take one at home with light monitoring. If you even suspect you could benefit, try it. They help a lot if you need them.

    #ChronicFatigue #Fibromyalgia #MECFS #ChronicIllness #CPAP

  5. This is actually a really good write up of #ChronicFatigue / #LongCovid in general even if it is framed from the point of view of joint pain.

    mastodon.social/ap/users/116...

  6. This is actually a really good write up of #ChronicFatigue / #LongCovid in general even if it is framed from the point of view of joint pain.

    mastodon.social/ap/users/116...

  7. Today's happy thing: my antihistamines have relieved my fatigue and it looks like I'm reaching a new baseline! Could still be a fluke but I am so unbelievably excited at the chance to get back to living
    #happy #MCAS #health #chronicfatigue

  8. Low Folate and B12 Proven to Drive Chronic Fatigue

    Summary: A precision human ecology and metabolic study challenged the superficial notion that chronic exhaustion is merely a byproduct of inadequate sleep. The research demonstrates that the m…
    #dining #cooking #diet #food #Nutrition #B12Deficiency #brainresearch #chronicfatigue #folate #neurobiology #neuroscience #nutrition #osakaMetropolitanUniversity
    diningandcooking.com/2663016/l

  9. Low Folate and B12 Proven to Drive Chronic Fatigue

    Summary: A precision human ecology and metabolic study challenged the superficial notion that chronic exhaustion is merely a byproduct of inadequate sleep. The research demonstrates that the m…
    #dining #cooking #diet #food #Nutrition #B12Deficiency #brainresearch #chronicfatigue #folate #neurobiology #neuroscience #nutrition #osakaMetropolitanUniversity
    diningandcooking.com/2663016/l

  10. DATE: May 28, 2026 at 11:23PM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: Vitamin B12 and folate deficiencies linked to chronic fatigue

    URL: sciencedaily.com/releases/2026

    Feeling constantly drained might not just be about poor sleep or working too hard. Researchers in Japan found that low levels of key vitamins — especially vitamin B12 and folate — may quietly contribute to fatigue and lack of motivation, even in otherwise healthy people.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #VitaminB12 #FolateDeficiency #ChronicFatigue #FatigueSolutions #VitaminB12 deficiency #FolateDeficiencySymptoms #EnergyBoost #HealthyLiving #NutritionResearch #JapanStudy

  11. DATE: May 28, 2026 at 11:23PM
    SOURCE: SCIENCE DAILY MIND-BRAIN FEED

    TITLE: Vitamin B12 and folate deficiencies linked to chronic fatigue

    URL: sciencedaily.com/releases/2026

    Feeling constantly drained might not just be about poor sleep or working too hard. Researchers in Japan found that low levels of key vitamins — especially vitamin B12 and folate — may quietly contribute to fatigue and lack of motivation, even in otherwise healthy people.

    URL: sciencedaily.com/releases/2026

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #VitaminB12 #FolateDeficiency #ChronicFatigue #FatigueSolutions #VitaminB12 deficiency #FolateDeficiencySymptoms #EnergyBoost #HealthyLiving #NutritionResearch #JapanStudy

  12. DATE: May 24, 2026 at 08:00PM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Low-dose ketamine shows promise for easing chronic fatigue

    URL: psypost.org/low-dose-ketamine-

    A single, low-dose intravenous infusion of ketamine reduced symptoms of chronic fatigue in patients suffering from various medical conditions, though the results were not statistically significant when compared to another sedative. The trial offers early evidence that ketamine and similar drugs might act quickly to relieve severe fatigue, paving the way for larger clinical trials in the future. The findings were published in Pharmacological Reports.

    Fatigue is a common and debilitating symptom for up to 90 percent of people dealing with chronic illnesses. Unlike ordinary tiredness, this type of condition is relentless, unpredictable, and does not improve with rest. Relentless exhaustion can severely disrupt daily life, employment, and mental well-being. The underlying causes of this condition remain poorly understood, though research points toward disrupted nervous system activity and chronic inflammation.

    Taichi Goto, a researcher at the National Institutes of Health, and a team of colleagues investigated alternative treatments for chronic fatigue. Their prior work found that fatigue in cancer patients who had undergone radiation therapy was linked to the stimulation of specific targets in the immune system. When certain glutamate receptors were active, they increased the production of inflammatory molecules. This systemic inflammation contributes heavily to feelings of deep exhaustion.

    Ketamine is a synthetic drug historically used as an anesthetic, though it has gained attention for its ability to treat severe depression. The drug works by blocking certain glutamate receptors in the brain and nervous system. It also increases levels of a special protein that promotes the survival and growth of neurons. The researchers suspected that this mechanism might interrupt the biological pathways responsible for chronic fatigue.

    An earlier analysis by the same research group hinted that ketamine could rapidly alleviate fatigue in people with bipolar disorder. In that study, the anti-fatigue effects began within forty minutes of the infusion and lasted for roughly two days. To test if this rapid relief translated to other illnesses, Goto and his team designed a new clinical trial targeting chronic fatigue across multiple medical conditions.

    The researchers enrolled ten adults into the study. The participants included cancer survivors as well as individuals diagnosed with fibromyalgia, systemic lupus erythematosus, and a condition known as myalgic encephalomyelitis or chronic fatigue syndrome. All the patients had experienced severe fatigue for an extended period, totaling at least six months of exhaustion over the past year.

    The study was designed as a randomized, double-blind crossover trial. Four of the participants received a low-dose infusion of ketamine during the first phase of the study, delivered intravenously over the course of forty minutes. After a two-week waiting period, these same participants returned to receive an infusion of midazolam. Midazolam is a fast-acting sedative often used in medical procedures to induce sleepiness and relieve anxiety.

    The other six participants received the exact same drugs, but in the reverse order. The researchers chose midazolam as the comparison drug because it mimics some of ketamine’s behavioral side effects, such as sedation and mild disorientation. This similarity was intended to keep the participants and the medical staff from guessing which drug was being administered at any given time.

    Patients rated their fatigue on a visual scale from zero to one hundred before the infusions and at several specific time points over the following week. The visual scale provided a real-time snapshot of the participants’ current level of exhaustion. The researchers primarily wanted to see if ketamine would reduce these fatigue scores by at least 20 percent by the third day after the infusion.

    When the researchers began examining the data, they noticed an unexpected pattern between the two phases of the study. At the start of the second phase, before the second drug was given, the participants reported lower baseline fatigue scores than they had at the very beginning of the trial. This meant the effects of the first phase were carrying over into the second phase, regardless of which drug was administered first.

    Because of this carryover effect, the researchers analyzed the two phases of the study separately. During the first phase, participants who received ketamine experienced a 21 percent decrease in their fatigue scores by the third day. The participants who received midazolam experienced a 17.7 percent decrease in their fatigue scores over the same period.

    During the second phase of the trial, the ketamine group saw a 10.9 percent drop in fatigue scores. The midazolam group saw a 12.6 percent drop. When comparing the two drugs in either phase, the differences in fatigue reduction were not statistically significant. This means the researchers could not definitively prove that ketamine worked better than midazolam in this specific sample of patients.

    Despite the lack of statistical dominance against the sedative, ketamine did meet the research team’s original benchmark for preliminary success in the first phase. The drug produced an overall reduction in fatigue that successfully exceeded the 20 percent goal at the three-day mark. The data showed that the most dramatic drop in exhaustion for the ketamine group happened one day after the infusion, with fatigue scores falling by 38.7 percent.

    The researchers acknowledged several limitations in their study. The trial initially aimed to recruit nearly sixty participants over a period of three years. Pandemic restrictions and strict eligibility criteria limited the final enrollment to just ten people. This unusually small group size makes it difficult to draw broad conclusions and increases the risk that the trial failed to capture the full differences between the two interventions.

    The crossover design of the study also complicated the results. The trial revealed that midazolam might not act as a neutral comparison drug for studying fatigue. While midazolam successfully mimicked the side effects of ketamine, it also appeared to reduce fatigue on its own. Midazolam interacts with a brain chemical called gamma-aminobutyric acid, which is known to be imbalanced in some chronic fatigue patients.

    Emerging evidence also suggests that midazolam might have anti-inflammatory properties of its own. By lowering systemic inflammation, the sedative might inadvertently ease the physical symptoms of exhaustion. Both ketamine and midazolam appeared to have fatigue-reducing effects, which obscured any relative advantages ketamine might have held over a truly inactive placebo.

    The blinding process in the study also appeared to be compromised. In surveys given after the trial, both the participants and the clinicians accurately guessed which drug was being administered most of the time. This awareness could have triggered a placebo effect, contributing to the unexpected improvements seen during the second phase of the study.

    The varied medical conditions of the participants might also play a role in how the drugs interacted with their bodies. The biological roots of exhaustion in cancer survivors largely involve the hormonal stress response and systemic inflammation. Meanwhile, the causes of fatigue in autoimmune disorders are primarily tied to specific immune proteins. A deeper understanding of these underlying mechanisms could eventually impact how patients respond to different pharmaceutical interventions.

    Future trials will likely need to abandon the crossover design to avoid lingering effects between drug administration periods. The researchers noted that scientists should identify a different control drug that does not actively reduce inflammation or interact with the central nervous system in ways that alleviate tiredness. They also suggested measuring the highest anti-fatigue effects one day after the infusion to better capture ketamine’s rapid action.

    The study, “A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial,” was authored by Taichi Goto, Joy D. Kreskow, Alexander L. R. Ross, Catherine L. Blumhorst, Justin J. Zhao, Andrew J. Mannes, Miroslav Bačkonja, Carlos A. Zarate Jr, and Leorey N. Saligan.

    URL: psypost.org/low-dose-ketamine-

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ketaminefatigue #chronicfatigue #fatigueresearch #neuroscience #inflammation #clinicaltrials #biomarkers #fatiguerelief #psychopharmacology #MECFS

  13. DATE: May 24, 2026 at 08:00PM
    SOURCE: PSYPOST.ORG

    ** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
    -------------------------------------------------

    TITLE: Low-dose ketamine shows promise for easing chronic fatigue

    URL: psypost.org/low-dose-ketamine-

    A single, low-dose intravenous infusion of ketamine reduced symptoms of chronic fatigue in patients suffering from various medical conditions, though the results were not statistically significant when compared to another sedative. The trial offers early evidence that ketamine and similar drugs might act quickly to relieve severe fatigue, paving the way for larger clinical trials in the future. The findings were published in Pharmacological Reports.

    Fatigue is a common and debilitating symptom for up to 90 percent of people dealing with chronic illnesses. Unlike ordinary tiredness, this type of condition is relentless, unpredictable, and does not improve with rest. Relentless exhaustion can severely disrupt daily life, employment, and mental well-being. The underlying causes of this condition remain poorly understood, though research points toward disrupted nervous system activity and chronic inflammation.

    Taichi Goto, a researcher at the National Institutes of Health, and a team of colleagues investigated alternative treatments for chronic fatigue. Their prior work found that fatigue in cancer patients who had undergone radiation therapy was linked to the stimulation of specific targets in the immune system. When certain glutamate receptors were active, they increased the production of inflammatory molecules. This systemic inflammation contributes heavily to feelings of deep exhaustion.

    Ketamine is a synthetic drug historically used as an anesthetic, though it has gained attention for its ability to treat severe depression. The drug works by blocking certain glutamate receptors in the brain and nervous system. It also increases levels of a special protein that promotes the survival and growth of neurons. The researchers suspected that this mechanism might interrupt the biological pathways responsible for chronic fatigue.

    An earlier analysis by the same research group hinted that ketamine could rapidly alleviate fatigue in people with bipolar disorder. In that study, the anti-fatigue effects began within forty minutes of the infusion and lasted for roughly two days. To test if this rapid relief translated to other illnesses, Goto and his team designed a new clinical trial targeting chronic fatigue across multiple medical conditions.

    The researchers enrolled ten adults into the study. The participants included cancer survivors as well as individuals diagnosed with fibromyalgia, systemic lupus erythematosus, and a condition known as myalgic encephalomyelitis or chronic fatigue syndrome. All the patients had experienced severe fatigue for an extended period, totaling at least six months of exhaustion over the past year.

    The study was designed as a randomized, double-blind crossover trial. Four of the participants received a low-dose infusion of ketamine during the first phase of the study, delivered intravenously over the course of forty minutes. After a two-week waiting period, these same participants returned to receive an infusion of midazolam. Midazolam is a fast-acting sedative often used in medical procedures to induce sleepiness and relieve anxiety.

    The other six participants received the exact same drugs, but in the reverse order. The researchers chose midazolam as the comparison drug because it mimics some of ketamine’s behavioral side effects, such as sedation and mild disorientation. This similarity was intended to keep the participants and the medical staff from guessing which drug was being administered at any given time.

    Patients rated their fatigue on a visual scale from zero to one hundred before the infusions and at several specific time points over the following week. The visual scale provided a real-time snapshot of the participants’ current level of exhaustion. The researchers primarily wanted to see if ketamine would reduce these fatigue scores by at least 20 percent by the third day after the infusion.

    When the researchers began examining the data, they noticed an unexpected pattern between the two phases of the study. At the start of the second phase, before the second drug was given, the participants reported lower baseline fatigue scores than they had at the very beginning of the trial. This meant the effects of the first phase were carrying over into the second phase, regardless of which drug was administered first.

    Because of this carryover effect, the researchers analyzed the two phases of the study separately. During the first phase, participants who received ketamine experienced a 21 percent decrease in their fatigue scores by the third day. The participants who received midazolam experienced a 17.7 percent decrease in their fatigue scores over the same period.

    During the second phase of the trial, the ketamine group saw a 10.9 percent drop in fatigue scores. The midazolam group saw a 12.6 percent drop. When comparing the two drugs in either phase, the differences in fatigue reduction were not statistically significant. This means the researchers could not definitively prove that ketamine worked better than midazolam in this specific sample of patients.

    Despite the lack of statistical dominance against the sedative, ketamine did meet the research team’s original benchmark for preliminary success in the first phase. The drug produced an overall reduction in fatigue that successfully exceeded the 20 percent goal at the three-day mark. The data showed that the most dramatic drop in exhaustion for the ketamine group happened one day after the infusion, with fatigue scores falling by 38.7 percent.

    The researchers acknowledged several limitations in their study. The trial initially aimed to recruit nearly sixty participants over a period of three years. Pandemic restrictions and strict eligibility criteria limited the final enrollment to just ten people. This unusually small group size makes it difficult to draw broad conclusions and increases the risk that the trial failed to capture the full differences between the two interventions.

    The crossover design of the study also complicated the results. The trial revealed that midazolam might not act as a neutral comparison drug for studying fatigue. While midazolam successfully mimicked the side effects of ketamine, it also appeared to reduce fatigue on its own. Midazolam interacts with a brain chemical called gamma-aminobutyric acid, which is known to be imbalanced in some chronic fatigue patients.

    Emerging evidence also suggests that midazolam might have anti-inflammatory properties of its own. By lowering systemic inflammation, the sedative might inadvertently ease the physical symptoms of exhaustion. Both ketamine and midazolam appeared to have fatigue-reducing effects, which obscured any relative advantages ketamine might have held over a truly inactive placebo.

    The blinding process in the study also appeared to be compromised. In surveys given after the trial, both the participants and the clinicians accurately guessed which drug was being administered most of the time. This awareness could have triggered a placebo effect, contributing to the unexpected improvements seen during the second phase of the study.

    The varied medical conditions of the participants might also play a role in how the drugs interacted with their bodies. The biological roots of exhaustion in cancer survivors largely involve the hormonal stress response and systemic inflammation. Meanwhile, the causes of fatigue in autoimmune disorders are primarily tied to specific immune proteins. A deeper understanding of these underlying mechanisms could eventually impact how patients respond to different pharmaceutical interventions.

    Future trials will likely need to abandon the crossover design to avoid lingering effects between drug administration periods. The researchers noted that scientists should identify a different control drug that does not actively reduce inflammation or interact with the central nervous system in ways that alleviate tiredness. They also suggested measuring the highest anti-fatigue effects one day after the infusion to better capture ketamine’s rapid action.

    The study, “A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial,” was authored by Taichi Goto, Joy D. Kreskow, Alexander L. R. Ross, Catherine L. Blumhorst, Justin J. Zhao, Andrew J. Mannes, Miroslav Bačkonja, Carlos A. Zarate Jr, and Leorey N. Saligan.

    URL: psypost.org/low-dose-ketamine-

    -------------------------------------------------

    DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.

    Private, vetted email list for mental health professionals: clinicians-exchange.org

    Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

    NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot

    Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com

    EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE: subscribe-article-digests.clin

    READ ONLINE: read-the-rss-mega-archive.clin

    It's primitive... but it works... mostly...

    -------------------------------------------------

    #psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ketaminefatigue #chronicfatigue #fatigueresearch #neuroscience #inflammation #clinicaltrials #biomarkers #fatiguerelief #psychopharmacology #MECFS

  14. Gee thanks, #adhd! What my #chronicfatigue really needed was new project ideas that are related enough to what I'm trying to do already I'll be constantly reminded of them, large enough to need non trivial effort, silly enough to be tempting and completely useless. Why not just hit all the high points at once?!

  15. Gee thanks, #adhd! What my #chronicfatigue really needed was new project ideas that are related enough to what I'm trying to do already I'll be constantly reminded of them, large enough to need non trivial effort, silly enough to be tempting and completely useless. Why not just hit all the high points at once?!

  16. Today in #ChronicFatigue : I hit a week of exercising every day, without skipping any. And given it has been 15 months since I stopped work, and this is the first time, I feel the need to celebrate that. In this state it is so easy to do too much and knock yourself out for the day(s) after.

    It does feel a bit strange to celebrate though, because exercise in this context is 10 minutes at 4.5 km/h on a treadmill. For those of you not used to metric measures, this is a ludicrously minimal amount of exertion; I normally walk at around 6 km/h and ten minutes is, well, ten minutes. And if I try and do this twice too close together (like walking to get an ice cream, sitting for half an hour, and walking back) I wreck my energy levels and sleep for the following several days.

  17. Today in #ChronicFatigue : I hit a week of exercising every day, without skipping any. And given it has been 15 months since I stopped work, and this is the first time, I feel the need to celebrate that. In this state it is so easy to do too much and knock yourself out for the day(s) after.

    It does feel a bit strange to celebrate though, because exercise in this context is 10 minutes at 4.5 km/h on a treadmill. For those of you not used to metric measures, this is a ludicrously minimal amount of exertion; I normally walk at around 6 km/h and ten minutes is, well, ten minutes. And if I try and do this twice too close together (like walking to get an ice cream, sitting for half an hour, and walking back) I wreck my energy levels and sleep for the following several days.

  18. Hi there,

    I just wanted to surface a Reddit post here on the fediverse. A very severe/extreme ME/CFS sufferer is currently in a precarious situation and needing financial support.

    Her name is Ali and you can read more about her situation on Reddit here:

    reddit.com/r/cfs/comments/1t11

    Thanks.

    #MECFS #MyalgicEncephalomyelitis #CFS #MyalgicE #ChronicIllness #ChronicFatigue #ChronicFatigueSyndrome #spoonie #spoonies

  19. Hi there,

    I just wanted to surface a Reddit post here on the fediverse. A very severe/extreme ME/CFS sufferer is currently in a precarious situation and needing financial support.

    Her name is Ali and you can read more about her situation on Reddit here:

    reddit.com/r/cfs/comments/1t11

    Thanks.

    #MECFS #MyalgicEncephalomyelitis #CFS #MyalgicE #ChronicIllness #ChronicFatigue #ChronicFatigueSyndrome #spoonie #spoonies

  20. xoxo.zone/users/Ashedryden/s...

    Oof. This. The combination of #adhd and #chronicfatigue is a life of constant war between "you should rest immediately when you need to" and "here is your reminder of critical thing that if you don't do it right now it will drop into a black hole for ever"

  21. xoxo.zone/users/Ashedryden/s...

    Oof. This. The combination of #adhd and #chronicfatigue is a life of constant war between "you should rest immediately when you need to" and "here is your reminder of critical thing that if you don't do it right now it will drop into a black hole for ever"

  22. I have washing up’d! (Raised the plates? Levitated the dishes? Why do we wash ‘up’ anyway?)

    English be weird. And yes, it may seem strange to some of you that having done the washing up is worth celebrating but sometimes it most definitely is: blog.mavnn.eu/2022/10/14/adh...

  23. I have washing up’d! (Raised the plates? Levitated the dishes? Why do we wash ‘up’ anyway?)

    English be weird. And yes, it may seem strange to some of you that having done the washing up is worth celebrating but sometimes it most definitely is: blog.mavnn.eu/2022/10/14/adh...

  24. @[email protected] Thanks. One of the things I hate about the combination of #chronicfatigue brain fog and #adhd impulsivity is that I know there's a huge danger of my brain just randomly starting sealioning and mansplaining across the people I follow as my brain just starts spewing random responses to stimuli. At least on this occasion I noticed...

  25. @[email protected] Thanks. One of the things I hate about the combination of #chronicfatigue brain fog and #adhd impulsivity is that I know there's a huge danger of my brain just randomly starting sealioning and mansplaining across the people I follow as my brain just starts spewing random responses to stimuli. At least on this occasion I noticed...

  26. bonfire.mavnn.eu/pub/objects...

    Using #krita practice to avoid vitamin D deficiency part 2.

    Turns out that when you're suffering from #chronicfatigue and don't have the energy to walk anywhere, it's really easy to get vitamin D deficiency because of the lack of sunlight. Last year I ended up needing to inject myself with extra vitamin D to get back to workable levels, this year I'm trying to be deliberate not repeating that experience.

    Public service announcement over, tl;dr get some sunlight, don't give yourself skin cancer either

  27. bonfire.mavnn.eu/pub/objects...

    Using #krita practice to avoid vitamin D deficiency part 2.

    Turns out that when you're suffering from #chronicfatigue and don't have the energy to walk anywhere, it's really easy to get vitamin D deficiency because of the lack of sunlight. Last year I ended up needing to inject myself with extra vitamin D to get back to workable levels, this year I'm trying to be deliberate not repeating that experience.

    Public service announcement over, tl;dr get some sunlight, don't give yourself skin cancer either

  28. I just wanted to say a huge thank you to MEAction Network (meaction.net/) and Visible (makevisible.com/) for the Visible band I won last month 👍 Having had ME/CFS for over 15 years I thought I knew everything about pacing but the Visible band has even taught this old dog some new tricks. Very cool 😎

    #MECFS #MEAction #MyalgicE #MyalgicEncephalomyelitis #ChronicFatigue #ChronicFatigueSyndrome #ChronicIllness #CFS #Spoons #Spoonie #Pacing #Health #Visible #Visibleband

  29. I just wanted to say a huge thank you to MEAction Network (meaction.net/) and Visible (makevisible.com/) for the Visible band I won last month 👍 Having had ME/CFS for over 15 years I thought I knew everything about pacing but the Visible band has even taught this old dog some new tricks. Very cool 😎

    #MECFS #MEAction #MyalgicE #MyalgicEncephalomyelitis #ChronicFatigue #ChronicFatigueSyndrome #ChronicIllness #CFS #Spoons #Spoonie #Pacing #Health #Visible #Visibleband